TNYA
Tenaya TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
TNYA vs peer average
80/100
TNYA vs. peer average (B vs. D)
Grade spread
A 1 · C 2 · D 2 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
LXEO is the first available peer comparator.
Lexeo Therapeutics is the other direct peer the prior packet baseline ties to Tenaya’s 2026 10-K, which identifies LX2020 among programs aimed at the underlying genetic cause of PKP2-associated ARVC; this keeps the peer set specific enough for monitoring TN-401, but still too narrow for standard-conviction valuation support [#10-K-2026-03-11].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
TNYA
Tenaya Therapeutics
LXEO
Lexeo Therapeutics
Grade
B
F
Momentum
92
8
Value
41
41
Sentiment
37
0
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs LXEO
TNYA / LXEO
Grade Position
Above peers
TNYA vs. peer average (B vs. D)
80/100
Momentum
92
TNYAValue
41
TNYASentiment
37
TNYARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs TNYA
LXEO is the first peer returned for this comparison set.